Q&A: Acelyrin CEO Shao-Lee Lin details biotech's $540M IPO, finding 'diamonds in the rough'
Acelyrin started trading on the Nasdaq Friday morning in one of the largest biotech initial public offerings in recent memory, with $540 million in gross proceeds and potentially $621 million if underwriters exercise their 30-day option to buy more shares.
Endpoints News dialed up Shao-Lee Lin, the California drug developer’s CEO, on Thursday night in advance of Acelyrin’s $SLRN listing, which priced at $18, the high end of its proposed range. In a sign of market appetite for the late-stage immunology biotech, Acelyrin upped the size of its offering twice this week in the lead-up to its debut, growing from 20.6 million to 26.5 million shares before a final tally of 30 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.